NCT01445613

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,203 (actual)
• Sponsor: Abbott Medical Devices · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.

Conditions

• Carotid Artery Disease
• Stroke
• Amaurosis Fugax
• Transient Ischemic Attack (TIA)

Interventions

Type	Name	Description
DEVICE	RX Acculink Carotid Stent System (RX Acculink)	Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.

Timeline

• Start date: 2011-10-01
• Primary completion: 2014-12-01
• Completion: 2016-03-01
• First posted: 2011-10-04
• Last updated: 2016-08-12
• Results posted: 2016-04-12

Locations

1 site across 1 country: United States